|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000300 USD | 0.00% |
|
-98.76% | -98.80% |
| 03-16 | Sofgen Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2024 | CI |
| 03-15 | Sofgen Pharma S.A. Auditor Raises 'Going Concern' Doubt | CI |
| Capitalization | 57.83M 49.38M 45.25M 42.78M 79.21M 5.53B 79.62M 539M 210M 2.63B 217M 212M 9.13B | P/E ratio 2023 |
10.2x | P/E ratio 2024 | -3.44x |
|---|---|---|---|---|---|
| Enterprise value | 334M 285M 262M 247M 458M 31.99B 460M 3.11B 1.21B 15.18B 1.25B 1.23B 52.77B | EV / Sales 2023 |
1.78x | EV / Sales 2024 | 1.45x |
| Free-Float |
10.73% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 week | -98.76% | ||
| Current month | -98.80% | ||
| 1 month | -99.70% | ||
| 3 months | -98.76% | ||
| 6 months | -99.98% | ||
| Current year | -98.80% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.03 |
| Current year | 0 | | 1.03 |
| 1 year | 0 | | 1.45 |
| 3 years | 0 | | 4.95 |
| 5 years | 0 | | 11.98 |
| 10 years | 0 | | 11.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 28/01/2025 | |
Melissa Angelini
CEO | Chief Executive Officer | - | 28/01/2025 |
Daniel Bernal
DFI | Director of Finance/CFO | - | 18/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 18/01/2023 | |
| Chairman | 68 | 18/12/2024 | |
| Director/Board Member | - | 18/12/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -98.76% | -99.98% | -99.99% | 698K | |
| +2.70% | +2.89% | +36.12% | +133.73% | 883B | |
| +2.63% | +2.60% | +55.25% | +44.44% | 540B | |
| +0.31% | +1.89% | +11.12% | +42.51% | 367B | |
| -0.62% | +0.47% | +22.18% | +12.38% | 328B | |
| +0.13% | +1.47% | +35.23% | +14.72% | 288B | |
| +0.78% | +2.87% | +27.40% | +26.23% | 283B | |
| +0.66% | +0.13% | +48.39% | -2.29% | 278B | |
| +0.91% | +2.12% | -31.78% | -48.50% | 206B | |
| +0.13% | +1.75% | +24.58% | +44.27% | 181B | |
| Average | +0.88% | +1.15% | +12.85% | +16.75% | 335.37B | |
| Weighted average by Cap. | +1.36% | +0.78% | +30.50% | +50.91% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 424M 362M 332M 313M 580M 40.56B 583M 3.95B 1.54B 19.25B 1.59B 1.56B 66.89B | 374M 319M 292M 277M 512M 35.77B 515M 3.48B 1.36B 16.98B 1.4B 1.37B 59.01B |
| Net income | 40.34M 34.45M 31.57M 29.84M 55.26M 3.86B 55.55M 376M 146M 1.83B 151M 148M 6.37B | -68.3M -58.33M -53.44M -50.52M -93.56M -6.54B -94.04M -636M -248M -3.1B -256M -251M -10.78B |
| Net Debt | 295M 252M 231M 218M 404M 28.25B 406M 2.75B 1.07B 13.4B 1.11B 1.08B 46.59B | 276M 236M 216M 205M 379M 26.46B 381M 2.58B 1B 12.56B 1.04B 1.02B 43.64B |
Employees
4,498
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/05/26 | 0.000300 $ | 0.00% | 100 |
- Stock Market
- Equities
- PROC.F Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition